Major shareholder announcement / Porter Orlin LLC

Announcement
16.12.2011


NeuroSeach A/S (NEUR) has received information from Porter Orlin LLC, New York, that the company has increased its voting rights in NeuroSearch A/S attached to shares owned by other companies.

Hereafter, Porter Orlin LLC administers a total of 2,481,804 shares of DKK 20 nominal value corresponding to a total ownership and voting rights of 10.11%.


Patrik Dahlen
CEO


Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097



About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS) disorders. The vision is to develop NeuroSearch into a profitable specialty pharmaceutical company. The strategy is primarily to complete the development and subsequently to market Huntexil^®, a unique drug in clinical Phase III for the treatment of the motor symptoms of Huntington’s disease.
Among discontinuing activities, NeuroSearch also has a portfolio of assets for outlicensing or divestment. This includes tesofensine which has shown outstanding efficacy in the treatment of obesity, the Integrative Screening Process (ISP), which is a proprietary systems biology approach, as well as a broad range of ion channel technologies and patented compounds identified as ion channel modulators.